References on Cancer Research Using ALZET^® Osmotic Pumps

Q0773 Cuevas,P., Carceller,F., Angulo,J., Gonzalez-Corrochano,R., Cuevas-Bourdier,A., Gimenez-Gallego,G. Antiglioma effects of a new, low molecular mass, inhibitor of fibroblast growth factor. Neuroscience Letters 2011; 491(-1-):1-7. >>> Dobesilate; PBS; CSF/CNS (intratumoral); Rat; 2004; 27 days; Controls received mp w/ vehicle; cancer (glioma); Compound, also known as (2,5-dihydroxyphenyl-sulfonate or 2,5DHPS) is an FGF inhibitor; chemotherapeutic.

Q0753 Driessens,G., Nuttin,L., Gras,A., Maetens,J., Mievis,S., Schoore,M., Velu,T., Tenenbaum,L., Preat,V., Bruyns,C. Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery. CANCER IMMUNOLOGY IMMUNOTHERAPY 2011; 60(-2-):273-281. >>> Granulocyte macrophage colony-stimulating factor; SC; Rat; 2004; 28 days; Animal info (male, inbred, Fischer 344, 10-12 wks old); comparison of "all in-vivo therapy" vs mp; cancer.

Q0709 Kurio,N., Shimo,T., Fukazawa,T., Takaoka,M., Okui,T., Hassan,N.M.M., Honami,T., Hatakeyama,S., Ikeda,M., Naomoto,Y., Sasaki,A. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAX and IGF-IR in vitro and in vivo. Experimental Cell Research 2011; 317(-8-):1134-1146. >>> Parathyroid hormone-related peptide (1-34); Saline, physiological; cysteine, L-; SC; Mice (nude); 1007D; ; Controls received mp w/ vehicle; animal info (5 wls old, male, BALB/c); cancer.

Q0757 Leksa,V., Loewe,R., Binder,B., Schiller,H.B., Eckerstorfer,P., Forster,F., Soler-Cardona,A., Ondrovicova,G., Kutejova,E., Steinhuber,E., Breuss,J., Drach,J., Petzelbauer,P., Binder,B.R., Stockinger,H. Soluble M6P/IGF2R Released by TACE Controls Angiogenesis via Blocking Plasminogen Activation. Circulation Research 2011; 108(-6-):676-U323. >>> Peptide (18-36); scrambled peptide; SC; Mice (SCID); 1002; 15 days; Animal info (pathogen-free, 6 wks old, female, CB17, scid/scid); peptides; cancer; angiogenesis.

Q0697 Mathew,B., Lennon,F.E., Siegler,J., Mirzapoiazova,T., Mambetsariev,N., Sammani,S., Gerhold,L.M., LaRiviere,P.J., Chen,C.T., Garcia,J.G.N., Salgia,R., Moss,J., Singleton,P.A. The Novel Role of the Mu Opioid Receptor in Lung Cancer Progression: A Laboratory Investigation. Anesthesia and Analgesia 2011; 112(-3-):558-567. >>> Naltrexone, methyl; SC; Mice; 1002; 12 days; Controls received mp w/ PBS; animal info (MOR KO, C57BL/6 wt); cancer (lung); Methylnaltrexone (also known as MNTX) is a mu opioid receptor inhibitor.

Q0907 Saghafi,N., Lam,D.K., Schmidt,B.L. Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neuroscience Letters 2011; 488(-3-):247-251. >>> WIN55,212-2; ACEA; AM1241; DMSO; water; SC; Mice (nude); 2002; 2 weeks; Animal info (Foxn1 nu, athymic, 4-5 wks old, 20-25 g); cancer (oral); behavioral testing (mechanical allodynia); 50% DMSO used; wound clips used; pain.

Q0781 Schulte,A., Guenther,H.S., Phillips,H.S., Kemming,D., Martens,T., Kharbanda,S., Soriano,R.H., Modrusan,Z., Zapf,S., Westphal,M., Lamszus,K. A Distinct Subset of Glioma Cell Lines with Stem Cell-like Properties Reflects the Transcriptional Phenotype of Glioblastomas and Overexpresses CXCR4 as Therapeutic Target. Glia 2011; 59(-4-):590-602. >>> AMD3100; CSF/CNS (intratumoral); Mice; 2004; ; Controls received mp w/ PBS; animal info (6-8 wks old, NMRI-nu/nu); ALZET brain infusion kit 2 used; cancer (glioma).

Q0783 Zhai,H.Y., Heppner,F.L., Tsirka,S.E. Microglia/Macrophages Promote Glioma Progression. Glia 2011; 59(-3-):472-485. >>> Ganciclovir; macrophage/microglia inhibitory factor; tuftsin; CSF/CNS (intratumoral); Mice; 14, 28 days; Negative controls received mp w/ saline; animal info (12-16 wks old, male, CD11b-HSVTK +/-, 25-30 g, C57BL/6); cancer (glioma); Plastics One guide cannula used; macrophage/microglia inhibitory factor also known as MIF/TKP is a tripeptide; tuftsin also known as threonine-lysine-proline-arginin or TKPR.

Q0000 Ager,E.I., Chong,W.W., Wen,S.W., Christophi,C. Targeting the the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases. Cancer Cell International 2010; 10(-;-):U1-U12. >>> CGP42112A; Saline, physiological; Mice; 1004; 21 days; Control animals received no treatment; cancer (colorectal); animal info (male, CBA, 6-8 wks old); dose response; AT2R agonist.

Q0664 Argiles,J.M., Fontes-Oliveira,C.C., Fuster,G., Ametller,E., Figueras,M., Olivan,M., Lopez-Soriano,F.J., Qu,X.Y., Demuth,J., Stevens,P., Varbanov,A., Wang,F., Isfort,R.J., Busquets,S. PATTERNS OF GENE EXPRESSION IN MUSCLE AND FAT IN TUMOR-BEARING RATS: EFFECTS OF CRF2R AGONIST ON CACHEXIA. Muscle&Nerve 2010; 42(-6-):936-949. >>> PG-873637; SC; Rat; ; Controls received mp w/ NaCl; animal info (male, Wistar, 5 wks old); cancer; PG-873637 is a CRF2R agonist.

Q0582 Carcaboso,A.M., Elmeliegy,M.A., Shen,J., Juel,S.J., Zhang,Z.W.M., Calabrese,C., Tracey,L., Waters,C.M., Stewart,C.F. Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas. Cancer Research 2010; 70(-11-):4499-4508. >>> Topotecan; Water, sterile; SC; Mice (nude); 2001D; 8-12 hours; Animal info (CD1, nude); cancer (glioma).

Q0109 Chambliss,K.L., Wu,Q.A., Oltmann,S., Konaniah,E.S., Umetani,M., Korach,K.S., Thomas,G.D., Mineo,C., Yuhanna,I.S., Kim,S.H., Madak-Erdogan,Z., Maggi,A., Dineen,S.P., Roland,C.L., Hui,D.Y., Brekken,R.A., Katzenellenbogen,J.A., Katzenellenbogen,B.S., Shaul,P.W. Non-nuclear estrogen receptor-alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. Journal of Clinical Investigation 2010; 120(-7-):2319-2330. >>> Estradiol; estrogen-dendrimer conjugate; IP; Mice (nude); 3, 7 weeks; 72 hours; Controls received mp w/ empty dendrimer; cardiovascular; cancer (breast); animal info (female, ERE-Luc reporter, 10-13 weeks old; Ex3aERKO, 8-9 weeks old; C57BL/6 Apoe-/-, 6 weeks old; SCID, 8 weeks old); functionality of mp verified by serum agent levels; replacement therapy (ovariectomy; pumps replaced after 28 days); long-term study; photon recording with light emission tomography (LET) system with a CCD camera; Research Diets D10001.

Q0111 Demestre,M., Herzberg,J., Holtkamp,N., Hagel,C., Reuss,D., Friedrich,R.E., Kluwe,L., Von Deimling,A., Mautner,V.F., Kurtz,A. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. Journal of Neuro-oncology 2010; 98(-1-):11-19. >>> Imatinib mesylate; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (Plexiform neurofibromas); enzyme inhibitor (receptor tyrosine kinase); stress/adverse reaction: (see pg 13) "because of inflammation at the ALZET pump site, four mice of the treatment group had to be discontinued"; animal info (female, athymic nu/nu Balb/c); agent also known as Glivec or Gleevec.

Q0113 Ding,D., Kanaly,C.W., Bigner,D.D., Cummings,T.J., Herndon,JE II, Pastan,I., Raghavan,R., Sampson,J.H. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. Journal of Neuro-oncology 2010; 98(-1-):1-7. >>> MR1-1; Gadolinium-DTPA; Saline; albumin, human serum; CSF/CNS (parenchyma); Rat; 2ML2; 5 days; Toxicology; cancer (glioblastoma); no stress (see pg. 4); animal info (male, Fisher 344, 3 months old); dose-response (Fig.1); skin wounds closed with wound clips; behavioral testing (stepping and placing reflex and incline ramp climbing ability); CED (Convection-enhanced delivery) infusion; "All rats survived the entirety of the study without clinical or histological toxicity attributable to the study drugs." (p. 1); MR1-1 is a recomb. immunotoxin of a mAb-endotoxin frag; Plastics One cannula used; MRI; brain tissue distribution.

Q0114 Elazar,V., Adwan,H., Baeuerle,T., Rohekar,K., Golomb,G., Berger,M.R. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. International Journal of Cancer 2010; 126(-7-):1749-1760. >>> Oligonucleotide, phosphorothioate antisense; oligonucleotide, phosphorothioate missense; PBS; SC; Rat (nude); 4 weeks; Controls received mp w/ nonsense oligo; antisense (osteopontin, bone sialoprotein); cancer (breast); animal info (RNU nude, 6-8 weeks old); comparison of polymeric nanoparticles vs mp; pumps replaced after 2 weeks.

Q0871 Fernandez,C.A., Roy,R., Lee,S., Yang,J.A., Panigrahy,D., Van Vliet,K.J., Moses,M.A. The Anti-angiogenic Peptide, Loop 6, Binds Insulin-like Growth Factor-1 Receptor. Journal of Biological Chemistry 2010; 285(-53-):41886-41895. >>> Peptide, loop 6; IP; Mice (SCID); ; Controls received mp w/ PBS; peptides; enzyme inhibitor (metalloproteinase); cancer; Loop 6, anti-angiogenic peptide, is a smaller domain C-terminal portion of TIMP-2.

Q0129 Goda,M., Atagi,S., Amitani,K., Hobara,N., Kitamura,Y., Kawasaki,H. Nerve Growth Factor Suppresses Prostate Tumor Growth. JOURNAL OF PHARMACOLOGICAL SCIENCES 2010; 112(-4-):463-466. >>> Nerve growth factor; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ saline; cancer (prostate); animal info (BALB/c, Slc, 5 wks old, nu/nu).

Q0013 Goldshmit,Y., Munro,K., Leong,S.Y., Pebay,A., Turnley,A.M. LPA receptor expression in the central nervous system in health and following injury. Cell and Tissue Research 2010; 341(-1-):23-32. >>> ; CSF/CNS (cortex); Mice; 3 days; Cyanoacrylate adhesive; ALZET brain infusion kit used; cancer; animal info (C57BL/6, 3 months old); post op. care (metacam); no pump used.

Q0230 Ishii,Y., Sakamoto,T., Ito,R., Yanaga,K. Anti-angiogenic Therapy on Hepatocellular Carcinoma Development and Progression. Journal of Surgical Research 2010; 158(-1-):69-76. >>> FR-118487; Propylene glycol; IP; Rat; 2002; 6 weeks; Cancer (hepatocellular carcinoma); animal info (5 wks old, male, Fisher).

Q0589 Iwasa,T., Okamoto,I., Takezawa,K., Yamanaka,K., Nakahara,T., Kita,A., Koutoku,H., Sasamata,M., Hatashita,E., Yamada,Y., Kuwata,K., Fukuoka,M., Nakagawa,K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British Journal of Cancer 2010; 103(-1-):36-42. >>> YM-155; cisplatin; carboplatin; DMSO; IV; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; animal info (male, nude, BALB/cAnNCrj-nu/nu, 5 weeks old); 0.1% DMSO used; cancer.

Q0606 Kato,T., Natsume,A., Toda,H., Iwamizu,H., Sugita,T., Hachisu,R., Watanabe,R., Yuki,K., Motomura,K., Bankiewicz,K., Wakabayashi,T. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Therapy 2010; 17(-11-):1363-1371. >>> RNA, small interferring; Mice; 1007D; 1 week; Animal info (6 wks old, female NOD-SCID); MGMT-siRNA/LipoTrust complex; O6-methylguanine- DNA methyltransferase; incorrectly stated 1003D pump; cancer.

Q0340 Lin,E., Wang,Q.C., Swenson,S., Jadvar,H., Groshen,S., Ye,W., Markland,F.S., Pinski,J. The Disintegrin Contortrostatin in Combination With Docetaxel Is a Potent Inhibitor of Prostate Cancer In Vitro and In Vivo. PROSTATE 2010; 70(-12-):1359-1370. >>> Contortrostatin; SC; Mice; 28 days; Controls received PBS IP; animal info (male, Nu/Nu, 5 wks old); cancer (prostate).

Q0584 Lynn,K.D., Udugamasooriya,D.G., Roland,C.L., Castrillon,D.H., Kodadek,T.J., Brekken,R.A. GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC CANCER 2010; 10(-;-):U1-U13. >>> GU81; IP; Mice; 19 days; Animal info (MMTV-PyMT/Fvb tg, 6 wks old); possibly Model 2004 used (100 ul in 19 days = 0.22 ul/hr); cancer (breast); GU81 is a VEGFR2 antagonist peptoid.

Q0206 Masunaga,S., Tano,K., Nakamura,J., Watanabe,M., Kashino,G., Takahashi,A., Tanaka,H., Suzuki,M., Ohnishi,K., Kinashi,Y., Liu,Y., Ohnishi,T., Ono,K. Usefulness of Hexamethylenetetramine as an Adjuvant to Radiation and Cisplatin in the Treatment of Solid Tumors: its Independency of p53 Status. Journal of Radiation Research 2010; 51(-1-):27-35. >>> Uridine, bromodeoxy; hexamethylenetetramine; Saline, physiological; SC; Mice (nude); 2001D; 2001; 7 days; 24 hours; Cancer; toxicology; animal info (6-7 weeks old, female, syngenic, Balb/Ca); labeling of P cells.

Q0860 Masunaga,S.I., Tano,K., Nakamura,J., Watanabe,M., Kashino,G., Suzuki,M., Kinashi,Y., Ono,K. Adverse effect of mild temperature hyperthermia combined with hexamethylenetetramine compared to its effect combined with tirapazamine in the treatment of solid tumors. EXPERIMENTAL AND THERAPEUTIC MEDICINE 2010; 1(-1-):169-174. >>> Uridine, 2-bromodeoxy 5-; tirapazamine; hexamethylenetetramine; Saline, physiological; SC; IP; Mice; 5 days; 24 hours; Animal info (syngeneic female C3H/He, 8-11 wks old); comparison of IP injections vs mp; cancer; labelling of P cells; "Continuous administration of HMTA and TPZ resulted in higher radio- and cisplatin-sensitizing effects than intraperitoneal single administration." pg 169.

P9917 Murray,B.W., Guo,C.X., Piraino,J., Westwick,J.K., Zhang,C., Lamerdin,J., Dagostino,E., Knighton,D., Loi,C.M., Zager,M., Kraynov,E., Popoff,I., Christensen,J.G., Martinez,R., Kephart,S.E., Marakovits,J., Karlicek,S., Bergqvist,S., Smeal,T. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2010; 107(-20-):9446-9451. >>> PF-3758309; Mice (nude); 9 days; Dose response; enzyme inhibitor (P21-activated kinsase); animal info (athymic, CRL breed, 6-8 weeks); cancer.

Q0306 Norrby,K., Nordenhem,A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS 2010; 118(-12-):949-957. >>> Dalteparin; epirubicin; Saline; SC; Rat; 2002; 2ML2; 14 days; Controls received mp w/ vehicle; animal info (adult, male, Sprague-Dawley, 6-7 wks old, 218-223 g.); cancer; multiple pumps per animal (2); dalteparin is a low-molecular-weight heparin; epirubicin is a chemotherapeutic.

Q0095 Schmidt,N.O., Ziu,M., Cargioli,T., Westphal,M., Giese,A., Black,P.M., Carroll,R.S. Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. Translational Oncology 2010; 3(-1-):43-49. >>> Furegrelate; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; tissue perfusion (tumor); functionality of mp verified by residual volume; stress/adverse reaction: (see pg. 46) "hemosiderin deposits"; cancer (glioma); ALZET brain infusion kit used; animal info (Swiss, 4-6 wks old).

Q0715 Shibata,M.A., Morimoto,J., Shibata,E., Kurose,H., Akamatsu,K., Li,Z.L., Kusakabe,M., Ohmichi,M., Otsuki,Y. Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer. BMC CANCER 2010; 10(-;-):U1-U14. >>> Raloxifene; DMSO; ethanol; SC; Mice; 2002; 6 weeks; Animal info (female, 6 wks old, BALB/c); long-term study; pumps replaced every other week; cancer (metastatic breast cancer); stress/adverse reaction: "one animal died from an overdose of anesthesia when the osmotic mini-pumps were changed" (see pg. 7 of 14); raloxifene is a novel selective estrogen receptor modulator; chemotherapeutic.

P9944 Agrawal,A., Min,D.H., Singh,N., Zhu,H.H., Birjiniuk,A., von Maltzahn,G., Harris,T.J., Xing,D.Y., Woolfenden,S.D., Sharp,P.A., Charest,A., Bhatia,S. Functional Delivery of siRNA in Mice Using Dendriworms. ACS Nano 2009; 3(-9-):2495-2504. >>> RNA, small interfering; epidermal growth factor receptor; dendriworm, dye-labeled; RNA, small interfering, GFP, dendriworm, dye-labeled; CSF/CNS (intratumoral); Mice; 3, 7 days; Tissue perfusion (tumor); cancer (glioblastoma); incorrectly stated pump model 2007; Plastics One cannula used; animial info (Swiss Webster).

P9878 Antczak,C., Kloepping,C., Radu,C., Genski,T., Mueller-Kuhrt,L., Siems,K., de Stanchina,E., Abramson,D.H., Djaballah,H. Revisiting Old Drugs as Novel Agents for Retinoblastoma: In Vitro and In Vivo Antitumor Activity of Cardenolides. INVESTIGATIVE OPHTHALMOLOGY&VISUAL SCIENCE 2009; 50(-7-):3065-3073. >>> Ouabain; DMSO; SC; Mice (SCID); 1007D; 19 days; Controls received mp w/ vehicle; pumps replaced every week; cancer (retinoblastoma); animal info (8 wks old, male); 10% DMSO used; bioluminescence; IVIS 200.

P9502 Armaiz-Pena,G.N., Mangala,L.S., Spannuth,W.A., Lin,Y.G., Jennings,N.B., Nick,A.M., Langley,R.R., Schmandt,R., Lutgendorf,S.K., Cole,S.W., Sood,A.K. Estrous Cycle Modulates Ovarian Carcinoma Growth. Clinical Cancer Research 2009; 15(-9-):2971-2978. >>> Estradiol, 17b-; progesterone; megestrol acetate; Cyclodextrin, b-; water; SC; Mice (nude); ; Replacement therapy (ovariectomy); animal info (female, athymic); cancer (ovarian).

Q0602 Beauparlant,P., Bedard,D., Bernier,C., Chan,H., Gilbert,K., Goulet,D., Gratton,M.O., Lavoie,M., Roulston,A., Turcotte,E., Watson,M. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anti-cancer Drugs 2009; 20(-5-):346-354. >>> GMX1777; NaCl; IV (jugular); Mice; 2001D; 24 hours; Controls received mp w/ vehicle; animal info (CB17, SCID/SCID, female); comparison of 72 h infusion pump vs 24 h mp; cancer (refractory solid tumors and lymphomas); "The 24 h infusion was the most effective administration schedule identified in mouse xenograft models" pg 352-353; cancer.

P9597 Beauvais,D.M., Ell,B.J., McWhorter,A.R., Rapraeger,A.C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. Journal of Experimental Medicine 2009; 206(-3-):691-705. >>> Synstatin (82-130); synstatin (94-119); synstatin (92-119); cyclic RGDfv; cyclic RADfv; PBS; DMSO; H2O, double distilled; Mice (nude); 2004; 4 weeks; Controls received mp w/vehicle, or PBS; cancer; peptides; animal info (6-8 wks old, female, athymic, BALB/c); 50% DMSO used.

Q0586 Dilda,P.J., Decollogne,S., Weerakoon,L., Norris,M.D., Haber,M., Allen,J.D., Hogg,P.J. Optimization of the Antitumor Efficacy of a Synthetic Mitochondrial Toxin by Increasing the Residence Time in the Cytosol. Journal of Medicinal Chemistry 2009; 52(-20-):6209-6216. >>> Phenylarsonous acid; PBS; SC; Mice (nude); 1004; ; Controls received mp w/ vehicle; animal info (BalbC, nude, Female 7-9 week old); stability verified in vitro for at least 2 weeks at 4 or 37 degrees C; "There was a small accumulation of connective tissue at the delivery site of the osmotic pump in 7 of the 10 mice at the higher dose of PENAO. This is likely the result of a local inflammatory response triggered by the high concentrations of PENAO at the delivery site." pg 6213; Phenylarsonous acid (PENAO) is a cysteine mimetic analogue of CAO; cancer.

P9606 Harada,H., Itasaka,S., Kizaka-Kondoh,S., Shibuya,K., Morinibu,A., Shinomiya,K., Hiraoka,M. The Akt/mTOR Pathway Assures the Synthesis of HIF-1-alpha Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry 2009; 284(-8-):5332-5342. >>> Luciferin, D-; glucose, 2-deoxy-D-; PBS; water; SC; Mice (nude); ; Controls received mp/vehicle; cancer; animal info (6 weeks old, male, BALB/c, nu/nu) IVIS-200; bioluminescence.

Q0045 Inbar-Rozensal,D., Castiel,A., Visochek,L., Castel,D., Dantzer,F., Izraeli,S., Cohen-Armon,M. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. BREAST CANCER RESEARCH 2009; 11(-6-):U19-U29. >>> PJ-34; PBS; SC; Mice (nude); 14 days; controls received mp w/ vehicle or no treatment/no mp; enzyme inhibitor (poly-ADP-ribose polymerase); cancer (breast); no stress (R80); animal info (female, CD-1 nu/nu, 5-6 weeks old); "the 14-day treatment with a slow release of PJ-34 did not affect the vitality, growth, development, or any other behavior of the treated mice during the follow-up periods. (p. R80).

P9538 Kazi,A., Carie,A., Blaskovich,M.A., Bucher,C., Van,Thai, Moulder,S., Peng,H., Carrico,D., Pusateri,E., Pledger,W.J., Berndt,N., Hamilton,A., Sebti,S.M. Blockade of Protein Geranylgeranylation Inhibits Cdk2-Dependent p27Kip1 Phosphorylation on Thr187 and Accumulates p27Kip1 in the Nucleus: Implications for Breast Cancer Therapy. MOLECULAR AND CELLULAR BIOLOGY 2009; 29(-8-):2254-2263. >>> GGTI-2418; Polyethylene glycol; DMSO; SC; Mice (nude); 14 days; Controls received mp w/vehicle; cancer (breast); 20% DMSO used; enzyme inhibitor (geranylgeranyltransferase I).

P9774 Khan,N., Mupparaju,S.P., Hou,H., Lariviere,J.P., Demidenko,E., Swartz,H., Eastman,A. Radiotherapy in Conjunction with 7-Hydroxystaurosporine: A Multimodal Approach with Tumor pO2 as a Potential Marker of Therapeutic Response. RADIATION RESEARCH 2009; 172(--):592-597. >>> UCN-01; Sodium acetate; SC; Mice; 1003D; 3 days; Functionality of mp verified by plasma UCN-01 concentrations; cancer (radiation therapy); animal info (female, C3H/HEJ, 18-20 g.).

Q0440 Kilian,M., Gregor,J.I., Heukamp,I., Helmecke,K., Hanel,M., Wassersleben,B., Walz,M.K., Schimke,I., Kristiansen,G., Wenger,F.A. Impact of Octreotide and SOM-230 on liver metastasis and hepatic lipidperoxidation in ductal pancreatic adenocarcinoma in Syrian Hamster. CLINICAL&EXPERIMENTAL METASTASIS 2009; 26(-7-):719-727. >>> SOM-230; octreotide; SC; Hamster; 2004; 16 weeks; Animal info (120 wks old, male, Syrian Golden); long-term study; pumps replaced every 28 days; cancer (Ductal pancreatic).

P9619 Kitazoe,K., Abe,M., Hiasa,M., Oda,A., Amou,H., Harada,T., Nakano,A., Takeuchi,K., Hashimoto,T., Ozaki,S., Matsumoto,T. Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. International Journal of Hematology 2009; 89(-1-):45-57. >>> Valproic acid; PBS; SC; Mice (SCID); 2002; 14 days; Controls received mp w/vehicle; cancer (myeloma); animal info (8-10 wks old, female).

P9670 Lee,J.W., Shahzad,M.M.K., Lin,Y.G., rmaiz-Pena,G., Mangala,L.S., Han,H.D., Kim,H.S., Nam,E.J., Jennings,N.B., Halder,J., Nick,A.M., Stone,R.L., Lu,C.H., Lutgendorf,S.K., Cole,S.W., Lokshin,A.E., Sood,A.K. Surgical Stress Promotes Tumor Growth in Ovarian Carcinoma. Clinical Cancer Research 2009; 15(-8-):2695-2702. >>> Propranolol hydrochloride, S-; SC; Mice (nude); 2004; ; Controls received mp w/ PBS; no stress (see pg. 2697) "no significant complications"; cancer (ovarian); animal info (female, athymic, Ncr-nu).

P9800 Li,H., Wang,D.M., Zhang,H., Kirmani,K., Zhao,Z.W., Steinmetz,R., Xu,Y. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. MOLECULAR CANCER THERAPEUTICS 2009; 8(-6-):1692-1701. >>> Lysophosphatidic acid; PBS; IP; Mice; 1002; ; Pumps replaced after 14 days; cancer (epithelial ovarian); animal info (female, C57BL/6, 4-6 wks old); pumps siliconized with sigmacote to prevent LPA from adhering to pump walls.

Q0629 Maione,F., Molla,F., Meda,C., Latini,R., Zentilin,L., Giacca,M., Seano,G., Serini,G., Bussolino,F., Giraudo,E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. Journal of Clinical Investigation 2009; 119(-11-):3356-3372. >>> SM-216289; SC; Mice (transgenic); 1002; 2 weeks; Controls received mp w/ saline; animal info (RipTag2 Tg, 8.5 wks old); minipump and silastic tube were sutured to the abdominal wall; cancer.

P9692 Masunaga,S., Hirayama,R., Uzawa,A., Kashino,G., Suzuki,M., Kinashi,Y., Liu,Y., Koike,S., Ando,K., Ono,K. The effect of post-irradiation tumor oxygenation status on recovery from radiation-induced damage in vivo: with reference to that in quiescent cell populations. Journal of Cancer Research and Clinical Oncology 2009; 135(-8-):1109-1116. >>> Uridine, bromodeoxy-; Saline; SC; Mice; 5 days; Cancer; animal info (9 wks old, female, syngenic, C3H/He).

P9629 Minematsu,T., Iwai,M., Sugimoto,K., Shirai,N., Nakahara,T., Usui,T., Kamimura,H. Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9- dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells. Drug Metabolism and Disposition 2009; 37(-3-):619-628. >>> YM155, 14C-; SC; Mice (nude); 1003D; 3 days; Cancer; animal info (5 wks old, male, Balb/c-nu/nu); "YM155 showed high distribution to tumor tissues after continuous administration to nude mice bearing PC-3 tumors." pg 627.

P9661 Miyake,J.A., Benadiba,M., Colquhoun,A. Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression. Lipids in Health and Disease 2009; 8(-;-):U1-U10. >>> Gamma linolenic acid; CSF, artificial; CSF/CNS (intratumoral); Rat; 2002; 14 days; Controls received mp w/vehicle; cancer (glioma); ALZET brain infusion kit used; animal info (adult, female, Wistar, 250-350).

P9572 Restall,C., Doherty,J., Bin Liu,H., Genovese,R., Paiman,L., Byron,K.A., Anderson,R.L., Dear,A.E. A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth. International Journal of Cancer 2009; 125(-2-):483-487. >>> Metacept 1; DMSO; cremophor; saline; SC; Mice; 26 days; Half-life (p.483) 20 min.; cancer (breast); animal info (female BALB/c); enzyme inhibitor (histone deacetylase).

P9817 Reynolds,A.R., Hart,I.R., Watson,A.R., Welti,J.C., Silva,R.G., Robinson,S.D., Da Violante,G., Gourlaouen,M., Salih,M., Jones,M.C., Jones,D.T., Saunders,G., Kostourou,V., Perron-Sierra,F., Norman,J.C., Tucker,G.C., Hodivala-Dilke,K.M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Medicine 2009; 15(-4-):392-400. >>> EMD 121974; S 36578; Saline; Mice; 2002; ; Controls received mp w/ vehicle; cancer; animal info (C57BL/6); S 36578 is a RGD- mimetic small molecule; EMD 121974 also known as Cilengitide; dose response (fig. 1, pg. 393).

Q0238 Richards,A., McGeechan,K., Niknam,M., Salomon,R., Kurek,C., Dong,Q.H., Patel,M.I. Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors?. ANZ JOURNAL OF SURGERY 2009; 79(-9-):641-647. >>> Celecoxib; DMSO; ethanol; water; SC; Mice (nude); 2004; 8 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced after 28 days; stress/adverse reaction (see pg. 646 "local skin dryness and erosion"); enzyme inhibitor (COX-2); cancer (prostate); incorrectly stated pump model 2400; 50% DMSO used; 15% ethanol used.

Q0673 Roland,C.L., Lynn,K.D., Toombs,J.E., Dineen,S.P., Udugamasooriya,D.G., Brekken,R.A. Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer. PLoS One 2009; 4(-11-):U41-U53. >>> GU81; IP; Mice; 1, 3, 4 weeks; Controls received IP IgG injection; animal info (6-8 wks old, female, NOD/SCID, BALB/c); cancer (breast).

P9618 Rousseau,J., Barth,R.F., Moeschberger,M.L., Elleaume,H. EFFICACY OF INTRACEREBRAL DELIVERY OF CARBOPLATIN IN COMBINATION WITH PHOTON IRRADIATION FOR TREATMENT OF F98 GLIOMA-BEARING RATS. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2009; 73(-2-):530-536. >>> Carboplatin; Dextrose; CSF/CNS (intratumoral); Rat; 2001; 6 days; Controls received mp w/vehicle; no stress (see pg. 532); cancer (glioma); ALZET brain infusion kit 2 used; animal info (male, Fisher, 230-260g); "Surgery for pump implantation was well tolerated." pg. 532; "It is noteworthy that the brainstem was not damaged by direct infusion of 200 ul of carboplatin (0.5 mg/mL) at a flow rate of 1uL/h." pg. 535; tissue perfusion (tumor).

P9819 Savai,R., Langheinrich,A.C., Schermuly,R.T., Pullamsetti,S.S., Dumitrascu,R., Traupe,H., Rau,W.S., Seeger,W., Grimminger,F., Banat,A. Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer. NEOPLASIA 2009; 11(-1-):48-56. >>> Bevacizumab; IV (jugular); Mice (nude); 2002; 14 days; Controls received mp w/ distilled water; animal info (female, C57BL/6, 5-7 wks old, BALB/c, nu/nu, 7-8 wks old); pump implated IP; bevacizumab is a anti-VEGF antibody; "This delivery (using ALZET pumps) mimics local delivery of antivascular agents and can be used effectively alone or in combination with cytotoxic chemotherapy for site-specific drug delivery for lung cancer treatment. As expected, continuous infusion of bevacizumab decreased lung tumor volume and tumor perfusion, with an added survival advantage compared to the untreated group." pg 55; cancer (lung); antibody.

P9478 Schauff,A.K., Kim,E.L., Leppert,J., Nadrowitz,R., Wuestenberg,R., Brockmann,M.A., Giese,A. Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation. Journal of Neuro-oncology 2009; 91(-3-):241-249. >>> Furegrelate; CSF/CNS (intratumoral); Mice (nude); 1002; 14 days; Controls were untreated; enzyme inhibitor (thromboxane synthase TXSA); cancer (glioma); tissue perfusion (tumor); ALZET brain infusion kit 3 used; animal info (NMRI).

P9579 Shah,D.K., Shin,B.S., Veith,J., Toth,K., Bernacki,R.J., Balthasar,J.P. Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy. Journal of Pharmacology and Experimental Therapeutics 2009; 329(-2-):580-591. >>> Topotecan; SC; IP; Mice; 1003D; 72 hours; Cancer (peritoneal).

P9727 Skipper,J.B., McNally,L.R., Rosenthal,E.L., Wang,W.Q., Buchsbaum,D.J. In vivo Efficacy of Marimastat and Chemoradiation in Head and Neck Cancer Xenografts. ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES 2009; 71(-1-):1-5. >>> Marimastat; DMSO; SC; Mice (nude); 2002; 14 days; Controls received mp w/vehicle; cancer; animal info (3 mo old, female).

Q0707 Tange,Y., Miyazaki,M., Iwata,J., Aiko,Y., Sakamoto,S., Mori,K. Novel Antitumor Effect of Carboplatin Delivered by Intracerebral Microinfusion in a Rat Malignant Glioma Model. NEUROLOGIA MEDICO-CHIRURGICA 2009; 49(-12-):572-579. >>> Carboplatin; Glucose, D-; Evans blue; CSF/CNS (intratumoral); Rat; 2001; 3, 7 days; Animal info (male, F344/N Slc, Fischer 220-260 g); brain tissue distribution; ALZET brain infusion kit used; stability verified (4 weeks) pg 573; cancer (glioma); MRI; brain tissue distribution; "... continuous intracerebral microinfusion using the osmotic mini-pump can provide broader distribution of agents than growth of the brain tumor."; "intracerebral microinfusion can attain clinically favorable drug distribution from a single infusion point." pg 576.

Q0812 Tsukioka,S., Uchida,J., Tsujimoto,H., Nakagawa,F., Sugimoto,Y., Oka,T., Kiniwa,M. Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: Evidence from a xenograft model of folate-depleted mice. Molecular Medicine Reports 2009; 2(-3-):393-398. >>> Fluorouracil, 5-; Sailne, sterile; SC; Mice; 2002; 14 days; Animal info (BALB/cA-nu/nu, 4-5 wks old); cancer (colorectal); "oral S-1/LV therapy inhibited the growth of COL-1 tumors more effectively than the infusion of 5-FU/LV when administered at doses of similar toxicity" pg 397.

P9574 Zhao,R., Raub,T.J., Sawada,G.A., Kasper,S.C., Bacon,J.A., Bridges,A.S., Pollack,G.M. Breast Cancer Resistance Protein Interacts with Various Compounds in Vitro, but Plays a Minor Role in Substrate Efflux at the Blood-Brain Barrier. Drug Metabolism and Disposition 2009; 37(-6-):1251-1258. >>> Cimetidine; alfuzosin; dipyridamole; DMSO; SC; Mice; 2001D; 24 hours; Functionality of mp verified by residual volume; cancer (breast); animal info (Mdrla KO, wt, abcg2 -/-); 50%, 80% DMSO used; "(with dipyridamole in 80% DMSO)" precipitation was visible around the exit hole at the end of the experiment" pg. 1255.

P8780 Albertsson,P., Lennernaes,B., Norrby,K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncologica 2008; 47(-2-):293-300. >>> Vinblastine sulfate; Saline, physiological; SC; Rat; 2001; 2ML1; 6-10 days; Controls received mp w/ vehicle; dose-response (fig. 2); no stress (see pg. 296); cancer; animal info (male, Sprague Dawley, 217-219g.).

P9137 Barkan,D., Kleinman,H., Simmons,J.L., Asmussen,H., Kamaraju,A.K., Hoenorhoff,M.J., Liu,Z.Y., Costes,S.V., Cho,E.H., Lockett,S., Khanna,C., Chambers,A.F., Green,J.E. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research 2008; 68(-15-):6241-6250. >>> ML-7; DMSO; Mice; 2004; 1 week; Controls received mp w/ vehicle; enzyme inhibitor (myosin light chain kinase, MLCK); cancer (breast); animal info (4-6 wks old, female, BALB/c, nu/nu).

P9389 Barth,R.F., Yang,W.L., Wu,G., Swindall,M., Byun,Y.J., Narayanasamy,S., Tjarks,W., Tordoff,K., Moeschberger,M.L., Eriksson,S., Binne,P.J., Riley,K.J. Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2008; 105(-45-):17493-17497. >>> N5-2OH; DMSO; CSF/CNS; Rat; 2001D; 24 hours; Controls received mp w/ vehicle; comparison of IT injections vs. mp; cancer (glioma); toxicology; animal info (Fisher); 30% DMSO used; 3-Carboranyl thymidine analog; "by administering N5-2OH at a much lower dose (500 ug vs. 30 mg for D-CDU) i.c.v. over 24h by Alzet pumps, we have markedly increased tumor boron uptake (27.6 ug/gm tumor) with undetectable amounts in normal brain and blood." (p. 17495).

P9286 Ciceroni,C., Arcella,A., Mosillo,P., Battaglia,G., Mastrantoni,E., Oliva,M.A., Carpinelli,G., Santoro,F., Sale,P., Ricci-Vitiani,L., De Maria,R., Pallini,R., Giangaspero,F., Nicoletti,F., Melchiorri,D. Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. Neuropharmacology 2008; 55(-4-):568-576. >>> LY379268; LY341495; SC; Mice (nude); 3 months; Controls received mp w/ saline; long-term study; pumps replaced every 15-28 days; cancer (brain, glioma); MRI; animal info (male, CD-1, nude); mGlu3 receptor-agonist, antagonist.

P9210 Cox,C.D., Coleman,P.J., Breslin,M.J., Whitman,D.B., Garbaccio,R.M., Fraley,M.E., Buser,C.A., Walsh,E.S., Hamilton,K., Schaber,M.D., Lobell,R.B., Tao,W., Davide,J.P., Diehl,R.E., Abrams,M.T., South,V.J., Huber,H.E., Torrent,M., Prueksaritanont,T., Li,C., Slaughter,D.E., Mahan,E., Fernandez-Metzler,C., Yan,Y., Kuo,L.C., Kohl,N.E., Hartman,G.D. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4- yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1- carboxamide (MK-0731) for the treatment of taxane-refractory cancer. Journal of Medicinal Chemistry 2008; 51(-14-):4239-4252. >>> MK-0731; piperidine analog, trans-fluoro-methylamine; Water; HCl; SC; Mice (nude); 2001D; 22 hours; Controls received mp w/ vehicle; dose-response (fig. 1); half-life (p.4246) 1 hour in rats; cancer (ovarian carcinoma); animal info (female, Crl: Nu/Nu-nuBR, 8-12 wks old, 25-30 g.); Kinesin spindle protein inhibitor; "subcutaneously implanted ALZET Osmotic Pumps were used for their ability to mimic a continuous iv infusion over the 22h course of the experiment... This protocol provides the best oppotunity to maintain plasma exposure for the required length of time without exposing the patient to high levels of drug following a bolus infusion." (p. 4243).

P9320 De Toni,A., Zbinden,M., Epstein,J.A., Altaba,A.R.I., Prochiantz,A., Caille,I. Regulation of survival in adult hippocampal and glioblastoma stem cell lineages by the homeodomain-only protein HOP. Neural Development 2008; 3(-;-):U2-U13. >>> Epidermal growth factor; fibroblast growth factor, basic; RNA, small interfering; Saline, physiological; CSF/CNS; CSF/CNS (dentate gyrus); Rat; 1003D; 3 days; Controls received mp w/ control siRNA; cancer (glioblastoma); peptides; animal info (Swiss, HOP -/-, wt, adult); HOP or control siRNA was coupled to the cell permeant peptide, penetratin.

P9319 DeAngelo,A.B., Daniel,F.B., Wong,D.M., George,M.H. The induction of hepatocellular neoplasia by trichloroacetic acid administered in the drinking water of the male B6C3F1 mouse. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES 2008; 71(-16-):1056-1068. >>> Uridine, bromodeoxy-; thymidine, 3H-; SC; Mice; 2001; 5 days; Cancer (hepatic); toxicology; animal info (B6C3F1, male, 7-107 wks old).

P8846 Dikmen,Z.G., Gellert,G.C., Dogan,P., Yoon,H., Lee,Y.B., Ahn,C.H., Shay,J.W. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. Journal of Cellular Biochemistry 2008; 104(-3-):985-994. >>> RX-0047; oligonucleotide, phosphorothioate antisense; SC; IP; Mice (nude); 1002; 14 days; Controls received no treatment; comparison of IP injections vs. mp; antisense (HIF-1a); cancer (lung, prostate); animal info (Nu/Nu).

P8817 Dings,R.P.M., Van Laar,E.S., Webber,J., Zhang,Y., Griffin,R.J., Waters,S.J., MacDonald,J.R., Mayo,K.H. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Letters 2008; 265(-2-):270-280. >>> Anginex; anginex topomimetic 0118; SC; Mice (nude); 28 days; Cancer (ovarian carcinoma); animal info (female, athymic nu/nu, 5-6 wks old); antiangiogenic.

P9170 Eichelbaum,E.J., Sun,Y., Alli,A.A., Gower,WR Jr, Vesely,D.L. Cardiac and kidney hormones cure up to 86% of human small-cell lung cancers in mice. European Journal of Clinical Investigation 2008; 38(-8-):562-570. >>> Natriuretic peptide, long acting; atrial natriuretic peptide; vessel dilator peptide; kaliuretic peptide; urodilatin; Saline; SC; Mice (nude); 1007D; 4 weeks; Controls received mp w/ vehicle; cancer (small cell lung); peptides; animal info (nu/nu, athymic); urodilatin is a kidney hormone.

P9382 Feldmann,G., Habbe,N., Dhara,S., Bisht,S., Alvarez,H., Fendrich,V., Beaty,R., Mullendore,M., Karikari,C., Bardeesy,N., Ouellette,M.M., Yu,W., Maitra,A. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008; 57(-10-):1420-1430. >>> Cyclopamine; Sodium citrate buffer; phosphate buffer; cyclodextrin, 2-hydroxy-propyl-beta-; SC; Mice (transgenic); 5, 61-67 days; Controls received mp w/ vehicle; long-term study; pumps replaced weekly; cancer (panreatic adenocarcinoma); multiple pumps per animal (2); animal info (Pdx1-Cre; LsL-Kras-G12D; Ink4a/ArF-lox/lox Tg, 5 wks old); "pharmacological Hedgehog blockage by continuous administration of low-dose cyclopamine prolongs survival in this model (of pancreatic cancer)." (p. 1420); 30% cyclodextrin used.

P9285 Feldmann,G., Fendrich,V., McGovern,K., Bedja,D., Bisht,S., Alvarez,H., Koorstra,J.B.M., Habbe,N., Karikari,C., Mullendore,M., Gabrielson,K.L., Sharma,R., Matsui,W., Maitra,A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. MOLECULAR CANCER THERAPEUTICS 2008; 7(-9-):2725-2735. >>> IPI-269609; Cyclodextrin, 2-hydroxypropyl-b-; water, sterile; SC; Mice (nude); 2002; 6 weeks; 5, 7 days; Controls received mp w/ vehicle; comparison of daily PO vs. mp; pumps replaced every 2 wks; no stress (see pg. 2734); cancer (pancreatic); multiple pumps per animal (2); animal info (male, athymic CD1 nu/nu, 6-12 wks old); 30% cyclodextrin; Hedgehog inhibitor; "at the applied doses there were no signs of toxicity, weight loss, or other signs of adverse events in mice during the described treatment periods." (p. 2734).

P8437 Henke,E., Perk,J., Vider,J., de Candia,P., Chin,Y., Solit,D.B., Ponomarev,V., Cartegni,L., Manova,K., Rosen,N., Benezra,R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. NATURE BIOTECHNOLOGY 2008; 26(-1-):91-100. >>> Oligonucleotide, antisense, peptide conjugated; oligonucleotide, phosphorothioate antisense; peptide, F3; TBS; SC; Mice (nude); mice; 1007D; 1002; 14, 21 days; Controls received mp w/ vehicle or control peptide and oligo in non-conjugated form, or rcId1-PCAO; comparison of IV injections vs. mp; pumps replaced after 14 days; no stress (see pg. 95, 97); stability verified after 24 hours in 37 C, plasma up to 28 days in 37 C saline; antisense (Id1, rcId1); cancer (breast, lung carcinoma); peptides; toxicology; animal info (female, nude NCR; male, C57J/B6); antisense oligos covalently coupled to address peptide that targets tumor endothelial cells; "no adverse effects on treated mice have been observed." (p. 97).

P9114 Iwasa,T., Okamoto,I., Suzuki,M., Nakahara,T., Yamanaka,K., Hatashita,E., Yamada,Y., Fukuoka,M., Ono,K., Nakagawa,K. Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines. Clinical Cancer Research 2008; 14(-20-):6496-6504. >>> YM155; Saline; Mice (nude); 1003D; 7 days; Controls received mp w/ vehicle; cancer (lung); animal info (BALB/c, athymic, 6 wks old, female); YM155 is a small inhibitor of survivin expression.

P8815 Jin,H.K., Yang,R.H., Zheng,Z., Romero,M., Ross,J., Bou-Reslan,H., Carano,R.A.D., Kasman,I., Mai,E., Young,J., Zha,J.P., Zhang,Z.M., Ross,S., Schwall,R., Colbern,G., Merchant,M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Research 2008; 68(-11-):4360-4368. >>> Hepatocyte growth factor, human; Dextran sulfate; IP; Mice (nude); 1002; ; Controls received mp w/ vehicle; functionality of mp verified by human HGF serum levels; long-term study; pumps replaced every 12 to 14 days; cancer (pancreatic); peptides; animal info (female, nu/nu).

P9768 Kang,G.S., Di Wang,X., Mohler,M.L., Kirichenko,O.V., Patil,R., Orr,W.E., Miller,D.D., Geisert,E.E. Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma. Anti-cancer Drugs 2008; 19(-9-):859-870. >>> EDL-155; HBSS; CSF/CNS (intratumoral); Rat; 2001; 7 days; Tissue perfusion (tumor); comparison of IP injections vs. mp; cancer (glioma); animal info (male, Sprague Dawley, 250-350 g); EDL-155 also known as 1-(biphenyl-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol.

P9117 Kasaoka,T., Nishiyama,H., Okada,M., Nakajima,M. Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models. CLINICAL&EXPERIMENTAL METASTASIS 2008; 25(-7-):827-834. >>> MMI270; DMSO; PEG 300; SC; Mice; 2004; 2004; 14; 21 days; Comparison of SC injections vs. mp; enzyme inhibitor (matrix metalloproteinase); cancer (melanoma); animal info (7 wks old, BDF1, male, lymphadrectomy; 50% DMSO used; 50% PEG 300.

P9204 Malcontenti-Wilson,C., Chan,L., Nikfarjam,M., Muralidharan,V., Christophi,C. Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. Journal of Gastroenterology and Hepatology 2008; 23(-7-):E96-E104. >>> Oxi4503; Saline, sterile; SC; Mice; 1002; ; Controls received mp w/ vehicle; dose-response (p. e99); comparison of IP injections vs. mp; half-life (p.e103) 6 hours; cancer (colon with liver metastases); animal info (male, CBA, 6-8 wks old); agent also known as combrestatin A-1 trans-stilbene.

P9680 Martens,T., Laabs,Y., Guenther,H.S., Kemming,D., Zhu,Z.P., Witte,L., Hagel,C., Westphal,M., Lamszus,K. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clinical Cancer Research 2008; 14(-17-):5447-5458. >>> Cetuximab; CSF/CNS (intratumoral); Mice (nude); 2004; ; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioblastoma); ALZET brain infusion kit 2 used; animal info (NMRI- nu/nu, 6-8 wks old); cetuximab is a monoclonal antibody against EGFR.

P9429 Masunaga,S.I., Ando,K., Uzawa,A., Hirayama,R., Furusawa,Y., Koike,S., Ono,K. Responses of total and quiescent cell populations in solid tumors to carbon ion beam irradiation (290 MeV/u) in vivo. Radiation Medicine 2008; 26(-5-):270-277. >>> Uridine, bromodeoxy-; Saline; SC; Mice; 5 days; Cancer (squamous cell carcinoma); animal info (female, C3H/He, 8-11 wks old).

P9728 Mersereau,J.E., Levy,N., Staub,R.E., Baggett,S., Zogric,T., Chow,S., Ricke,W.A., Tagliaferri,M., Cohen,I., Bjeldanes,L.F., Leitman,D.C. Liquiritigenin is a plant-derived highly selective estrogen receptor-beta agonist. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2008; 283(-1-2-):49-57. >>> Liquiritigenin; estradiol; SC; Mice (nude); 1 month; Controls received mp w/vehicle; cancer (breast); implies using 2ML4 pump (2.5ul/h); Liquiritigenin is a ER-beta selective compound extracted from the root of G. uralensis.

P9279 Mueller,L.U.W., Schore,R.J., Zheng,Y., Thomas,E.K., Kim,M.O., Cancelas,J.A., Gu,Y., Williams,D.A. Rac guanosine triphosphatases represent a potential target in AML. LEUKEMIA 2008; 22(-9-):1803-1806. >>> NSC23766; Mice (SCID); 28 days; Controls received mp w/ PBS; pumps replaced after 14 days; enzyme inhibitor (Rac GTPas); cancer (acute myeloid leukemia); multiple pumps per animal (2); animal info (NOD/SCID, irradiated).

P8811 Nagano,S., Perentes,J.Y., Jain,R.K., Boucher,Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Research 2008; 68(-10-):3795-3802. >>> Doxycycline; SC; Mice (SCID); 3 days; Controls received mp w/ saline; cancer (mammary carcinoma); animal info (SCID).

P9383 Nakagawa,H., Koyanagi,S., Kuramoto,Y., Yoshizumi,A., Matsunaga,N., Shimeno,H., Soeda,S., Ohdo,S. Modulation of circadian rhythm of DNA synthesis in tumor cells by inhibiting platelet-derived growth factor signaling. JOURNAL OF PHARMACOLOGICAL SCIENCES 2008; 107(-4-):401-407. >>> AG 1295; Saline, sterile; SC; Mice; 2001; 5 days; Controls received mp w/ vehicle; enzyme inhibitor (PDGF-receptor tyrosine kinase); cancer (sarcoma 180); animal info (male, ICR, 5 wks old); "continuous infusion administration of AG 1295 substantially decreased DNA synthesis in the tumor cells." (p. 406).

P9278 Nasr,R., Guillemin,M.C., Ferhi,O., Soilihi,H., Peres,L., Berthier,C., Rousselot,P., Robledo-Sarmiento,M., Lallemand-Breitenbach,V., Gourmel,B., Vitoux,D., Pandolfi,P.P., Rochette-Egly,C., Zhu,J., The,H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine 2008; 14(-12-):1333-1342. >>> Bortezomib; cyclic AMP; H89; SC; Mice (nude); mice (transgenic); 1, 3, 6, 7 days; Controls received no treatment; enzyme inhibitor (PKA); cancer (acute promyelocytic leukemia); animal info (nude, PLZF-RARA-RARA-PLZF; PML-RARA5873A Tg); Bortezomib is a proteasome inhibitor.

P9198 Rennel,E.S., Hamdollah-Zadeh,M.A., Wheatley,E.R., Magnussen,A., Schueler,Y., Kelly,S.P., Finucane,C., Ellison,D., Cebe-Suarez,S., Ballmer-Hofer,K., Mather,S., Stewart,L., Bates,D.O., Harper,S.J. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. European Journal of Cancer 2008; 44(-13-):1883-1894. >>> Vascular endothelial growth factor-165-b, recomb.; NaCl, sterile; SC; Mice; 28 days; No stress (see pg. 1888); half-life (p. 1893) 25 min in mice, 13.8-72 min in rats; cancer (colon); post op. care (Temgesic); animal info (C57/Bl6, 720 g.); silk sutures used; "no adverse effects were observed with this infusion of VEGF165b" pg. 1888; compound is an anti angiogenic isoform of VEGF.

P9251 Rosendahl,A.H., Holly,J.M.P., Celander,M., Forsberg,G. Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. International Journal of Cancer 2008; 123(-6-):1286-1291. >>> Insulin-like growth factor I, recomb. human; Saline, sterile; albumin, mouse serum; SC; Mice (SCID); 1007D; 14 days; Controls received mp w/ vehicle; cancer (renal carcinoma); peptides; animal info (female, SCID CoB-17, 8-12 wks old, 20 g.).

P8791 Song,P.F., Sekhon,H.S., Fu,X.W., Maier,M., Jia,Y.B., Duan,J., Proskosil,B.J., Gravett,C., Lindstrom,J., Mark,G.P., Saha,S., Spindel,E.R. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Research 2008; 68(-12-):4693-4700. >>> Darifenacin; DMSO; PBS; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; cancer (lung carcinoma); animal info (male, nu/nu); 50% DMSO; M3 mAChR antagonist.

P9202 Tejeda,M., Gaal,D., Hullan,L., Csuka,O., Schwab,R., Szokoloczi,O., Keri,G.Y. Continuous Administration of the Somatostatin Structural Derivative /TT-232/ by Subcutaneously Implanted Osmotic Pump Improves the Efficacy and Potency of Antitumor Therapy in Different Mouse and Human Tumor Models. Anticancer Research 2008; 28(-5A-):2769-2774. >>> TT-232; Water, distilled; acetic acid; sodium acetate; mannitol; SC; IV (jugular); Mice; 2001; 2002; 7; 14; 28 days; Comparison of IP and SC injections vs. SC and IV mp; pumps replaced after 2 weeks; PE-10 tubing used; "The frequent and long-lasting repetition of TT-232 injection enhanced its therapeutic efficacy; however, serial injection causes significant stress to animals and adequate precautions are required. To this end, an ALZET osmotic minipump inserted s.c. and i.v. was used." pg 2773; "The results obtained from this study suggest that TT-232 is a good candidate for delivery by continuous (infusion) therapy; cancer.

P9254 Xue,F., Takahara,T., Yata,Y., Xia,Q., Nonome,K., Shinno,E., Kanayama,M., Takahara,S., Sugiyama,T. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. HEPATOLOGY RESEARCH 2008; 38(-8-):810-817. >>> Y-27632; PBS; SC; Mice; 1002; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; enzyme inhibitor (Rho/ROCK); cancer (hepatocellular carcinoma); animal info (female, B6C3F1).

P9469 Yano,A., Tsutsumi,S., Soga,S., Lee,M.J., Trepel,J., Osada,H., Neckers,L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2008; 105(-40-):15541-15546. >>> Reveromycin A; SC; Mice (nude); 2004; 2.5 weeks; Controls received mp IP DMSO injections 2x/week; cancer (prostate carcinoma); animal info (male, nu/nu, 6 wks old); osteoclast-specific apoptosis-inducer.

P9077 Ye,L., Lewis-Russell,J.M., Sanders,A.J., Kynaston,H., Jiang,W.G. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 2008; 26(-2-):190-197. >>> Hepatocyte growth factor, recomb. human; NK4, recomb. human; SC; Mice (nude); 2004; 4 weeks; Cancer (prostate); animal info (athymic, male, CD-1, 4-6 wks old).

P9084 Zhang,J.J., Zafrullah,M., Yang,X., Yin,X.L., Zhang,Z.G., Fuks,Z., Kolesnick,R. Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake. CANCER BIOLOGY&THERAPY 2008; 7(-9-):1492-1497. >>> Oligonucleotide, antisense; PBS; SC; Mice; 5 days; Controls received mp w/ vehicle; antisense (KSR1); cancer (pancreatic).